Symbols / HEPA
HEPA Chart
About
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 464.81K |
| Enterprise Value | 53.17K | Income | -9.17M | Sales | — |
| Book/sh | 0.14 | Cash/sh | 0.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | 0.29 | P/C | — |
| EV/EBITDA | -0.01 | EV/Sales | — | Quick Ratio | 6.68 |
| Current Ratio | 10.77 | Debt/Eq | 6.45 | LT Debt/Eq | — |
| EPS (ttm) | -9.05 | EPS next Y | -11.43 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-04-16 16:00 | ROA | -72.99% |
| ROE | -6.28% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.62M |
| Shs Float | 11.62M | Short Float | 4.10% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 8.75 | 52W Low | 0.03 |
| Beta | 2.00 | Avg Volume | 14.82K | Volume | 2.00 |
| Target Price | — | Recom | None | Prev Close | $0.04 |
| Price | $0.04 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.04
Latest analyst target
3. DCF / Fair value
$-3.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.04
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-12-07 | down | Brookline Capital | Buy → Hold | — |
- Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - Stock Titan Mon, 12 May 2025 07
- Will HEPA stock split again soon - Market Weekly Review & Long Hold Capital Preservation Plans - mfd.ru Sat, 21 Feb 2026 14
- Hepion Pharmaceuticals Initiates Transition to OTC Markets Following Nasdaq Delisting Notice - Nasdaq Mon, 12 May 2025 07
- Hepion Pharmaceuticals to be delisted from Nasdaq - Investing.com Mon, 12 May 2025 07
- Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting' - Stocktwits Mon, 12 May 2025 07
- Hepion Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance Fri, 14 Mar 2025 07
- Aug Outlook: Is MCHP a top pick in the sector - Swing Trade & Weekly High Potential Alerts - baoquankhu1.vn ue, 24 Feb 2026 03
- Best Vacuums for Allergy Sufferers - Consumer Reports Mon, 25 Aug 2025 07
- Hepion Pharmaceuticals Executes Binding Letter of Intent with Ne - GuruFocus Wed, 07 May 2025 07
- 12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga hu, 22 Jan 2026 08
- Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today? - InvestorPlace Mon, 22 Apr 2024 07
- Hepion Pharmaceuticals faces potential Nasdaq delisting - Investing.com hu, 20 Mar 2025 07
- Hepion Pharma Urges Shareholder Support for Merger Amid Financial Challenges - Stock Titan Mon, 02 Dec 2024 08
- Aug Highlights: Is HEPA impacted by rising rates - Quarterly Risk Review & Technical Analysis for Trade Confirmation - baoquankhu1.vn Sun, 15 Feb 2026 03
- Hepion Pharmaceuticals Announces $9.0 Million Public Offering - GlobeNewswire Wed, 22 Jan 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 815.53K | -32.54K | -93.18K | 0.00 |
| TaxRateForCalcs | 0.18 | 0.01 | 0.06 | 0.00 |
| NormalizedEBITDA | -19.32M | -45.19M | -43.54M | -30.32M |
| TotalUnusualItems | 4.43M | -4.07M | -1.46M | -2.31M |
| TotalUnusualItemsExcludingGoodwill | 4.43M | -4.07M | -1.46M | -2.31M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.19M | -48.93M | -42.20M | -32.72M |
| ReconciledDepreciation | 30.76K | 67.13K | 77.46K | 86.07K |
| EBITDA | -14.88M | -49.26M | -45.00M | -32.63M |
| EBIT | -14.91M | -49.33M | -45.07M | -32.71M |
| NetInterestIncome | -1.25M | -9.46K | -10.16K | -8.86K |
| InterestExpense | 1.25M | 9.46K | 10.16K | 8.86K |
| NormalizedIncome | -16.81M | -44.89M | -40.84M | -30.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.19M | -48.93M | -42.20M | -32.72M |
| TotalExpenses | 19.35M | 45.26M | 43.62M | 30.40M |
| TotalOperatingIncomeAsReported | -19.35M | -48.45M | -45.49M | -30.40M |
| DilutedAverageShares | 122.89K | 79.42K | 76.23K | 70.29K |
| BasicAverageShares | 122.89K | 79.42K | 76.23K | 70.29K |
| DilutedEPS | -107.35 | -616.07 | -595.00 | -470.00 |
| BasicEPS | -107.35 | -616.07 | -595.00 | -470.00 |
| DilutedNIAvailtoComStockholders | -13.19M | -48.93M | -45.34M | -32.72M |
| NetIncomeCommonStockholders | -13.19M | -48.93M | -45.34M | -32.72M |
| OtherunderPreferredStockDividend | 0.00 | 3.14M | 0.00 | |
| PreferredStockDividends | 3.14M | |||
| NetIncome | -13.19M | -48.93M | -42.20M | -32.72M |
| NetIncomeIncludingNoncontrollingInterests | -13.19M | -48.93M | -42.20M | -32.72M |
| NetIncomeContinuousOperations | -13.19M | -48.93M | -42.20M | -32.72M |
| TaxProvision | -2.97M | -409.02K | -2.88M | 0.00 |
| PretaxIncome | -16.16M | -49.34M | -45.08M | -32.72M |
| OtherIncomeExpense | 4.43M | -4.07M | -1.46M | -2.31M |
| SpecialIncomeCharges | -3.17M | -3.19M | -1.87M | 0.00 |
| OtherSpecialCharges | 2.57M | |||
| WriteOff | 600.00K | 0.00 | ||
| ImpairmentOfCapitalAssets | 0.00 | 3.19M | 1.87M | 0.00 |
| GainOnSaleOfSecurity | 7.60M | -877.64K | 414.99K | -2.31M |
| NetNonOperatingInterestIncomeExpense | -1.25M | -9.46K | -10.16K | -8.86K |
| InterestExpenseNonOperating | 1.25M | 9.46K | 10.16K | 8.86K |
| OperatingIncome | -19.35M | -45.26M | -43.62M | -30.40M |
| OperatingExpense | 19.35M | 45.26M | 43.62M | 30.40M |
| ResearchAndDevelopment | 11.85M | 35.64M | 33.27M | 20.40M |
| SellingGeneralAndAdministration | 7.50M | 9.62M | 10.35M | 10.01M |
| GeneralAndAdministrativeExpense | 7.50M | 9.62M | 10.35M | 10.01M |
| OtherGandA | 7.50M | 9.62M | 10.35M | 10.01M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| PreferredSharesNumber | 87.27K | 87.27K | 87.38K | 1.81K |
| OrdinarySharesNumber | 139.17K | 96.37K | 76.23K | 76.22K |
| ShareIssued | 139.17K | 96.37K | 76.23K | 76.22K |
| NetDebt | 2.49M | |||
| TotalDebt | 2.90M | 209.02K | 53.61K | 316.99K |
| TangibleBookValue | -3.56M | 5.59M | 48.16M | 89.42M |
| InvestedCapital | -658.47K | 5.59M | 48.16M | 91.29M |
| WorkingCapital | -1.53M | 12.20M | 48.61M | 89.25M |
| NetTangibleAssets | -1.86M | 7.28M | 49.86M | 91.12M |
| CapitalLeaseObligations | 0.00 | 209.02K | 53.61K | 316.99K |
| CommonStockEquity | -3.56M | 5.59M | 48.16M | 91.29M |
| PreferredStockEquity | 1.70M | 1.70M | 1.70M | 1.70M |
| TotalCapitalization | -1.86M | 7.28M | 49.86M | 93.00M |
| TotalEquityGrossMinorityInterest | -1.86M | 7.28M | 49.86M | 93.00M |
| StockholdersEquity | -1.86M | 7.28M | 49.86M | 93.00M |
| GainsLossesNotAffectingRetainedEarnings | 8.35K | -78.78K | -90.17K | 0.00 |
| OtherEquityAdjustments | 8.35K | -78.78K | -90.17K | |
| RetainedEarnings | -237.82M | -224.63M | -175.70M | -133.50M |
| AdditionalPaidInCapital | 234.25M | 230.29M | 223.95M | 224.79M |
| CapitalStock | 1.70M | 1.70M | 1.70M | 1.71M |
| CommonStock | 14.00 | 10.00 | 381.00 | 7.62K |
| PreferredStock | 1.70M | 1.70M | 1.70M | 1.70M |
| TotalLiabilitiesNetMinorityInterest | 3.48M | 10.81M | 10.39M | 10.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 333.19K | 5.52M | 2.50M | 2.35M |
| OtherNonCurrentLiabilities | 1.63M | 2.09M | 1.89M | |
| DerivativeProductLiabilities | 333.19K | 3.80M | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 0.00 | 409.02K | 409.02K | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 409.02K | 409.02K | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 93.10K | 0.00 | 50.34K |
| LongTermCapitalLeaseObligation | 0.00 | 93.10K | 0.00 | 50.34K |
| CurrentLiabilities | 3.14M | 5.29M | 7.89M | 8.21M |
| OtherCurrentLiabilities | 386.00K | 366.23K | 2.99M | |
| CurrentDebtAndCapitalLeaseObligation | 2.90M | 115.92K | 53.61K | 266.65K |
| CurrentCapitalLeaseObligation | 0.00 | 115.92K | 53.61K | 266.65K |
| CurrentDebt | 2.90M | |||
| CurrentNotesPayable | 2.90M | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 1.91M | 1.64M | |
| PayablesAndAccruedExpenses | 243.89K | 4.79M | 5.56M | 3.31M |
| CurrentAccruedExpenses | 23.68K | 2.44M | 2.89M | 868.32K |
| Payables | 220.20K | 2.35M | 2.67M | 2.45M |
| TotalTaxPayable | 0.00 | |||
| AccountsPayable | 220.20K | 2.35M | 2.67M | 2.45M |
| TotalAssets | 1.61M | 18.09M | 60.24M | 103.55M |
| TotalNonCurrentAssets | -1.00 | 606.56K | 3.75M | 6.10M |
| OtherNonCurrentAssets | 364.19K | 426.17K | 583.33K | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 3.19M | 1.87M | |
| OtherIntangibleAssets | 3.19M | 3.19M | ||
| Goodwill | 0.00 | 1.87M | ||
| NetPPE | -1.00 | 242.37K | 3.32M | 3.65M |
| AccumulatedDepreciation | -420.73K | -379.47K | -306.94K | -240.24K |
| GrossPPE | 420.73K | 621.83K | 3.63M | 3.89M |
| OtherProperties | 358.55K | 559.65K | 326.38K | 330.83K |
| MachineryFurnitureEquipment | 62.18K | 62.18K | 62.18K | 62.18K |
| BuildingsAndImprovements | 212.88K | 3.24M | 3.49M | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 1.61M | 17.49M | 56.50M | 97.45M |
| PrepaidAssets | 1.21M | 2.70M | 5.31M | 6.10M |
| CashCashEquivalentsAndShortTermInvestments | 406.41K | 14.79M | 51.19M | 91.35M |
| CashAndCashEquivalents | 406.41K | 14.79M | 51.19M | 91.35M |
| CashFinancial | 406.41K | 14.79M | 51.19M | 91.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.22M | -40.90M | -34.98M | -31.35M |
| RepurchaseOfCapitalStock | 0.00 | -21.00M | 0.00 | |
| RepaymentOfDebt | 0.00 | -176.59K | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 2.50M | 0.00 | 17.86M | 82.15M |
| CapitalExpenditure | -14.30K | -16.34K | -130.41K | |
| InterestPaidSupplementalData | 0.00 | 0.00 | 941.00 | 2.02K |
| EndCashPosition | 406.41K | 14.79M | 51.19M | 91.35M |
| BeginningCashPosition | 14.79M | 51.19M | 91.35M | 40.73M |
| EffectOfExchangeRateChanges | 87.12K | 5.02K | -47.14K | 0.00 |
| ChangesInCash | -14.47M | -36.41M | -40.11M | 50.62M |
| FinancingCashFlow | 4.35M | 4.49M | -5.14M | 81.98M |
| CashFlowFromContinuingFinancingActivities | 4.35M | 4.49M | -5.14M | 81.98M |
| NetOtherFinancingCharges | -2.00M | |||
| ProceedsFromStockOptionExercised | 1.85M | 4.49M | 0.00 | 0.00 |
| NetPreferredStockIssuance | 0.00 | -3.14M | 0.00 | |
| PreferredStockPayments | 0.00 | -21.00M | 0.00 | |
| PreferredStockIssuance | 0.00 | 17.86M | 0.00 | |
| NetCommonStockIssuance | 2.50M | 0.00 | 0.00 | 82.15M |
| CommonStockIssuance | 2.50M | 0.00 | 0.00 | 82.15M |
| NetIssuancePaymentsOfDebt | 0.00 | -176.59K | ||
| NetLongTermDebtIssuance | 0.00 | -176.59K | ||
| LongTermDebtPayments | 0.00 | -176.59K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -600.00K | -14.30K | -14.07K | -130.41K |
| CashFlowFromContinuingInvestingActivities | -600.00K | -14.30K | -14.07K | -130.41K |
| NetOtherInvestingChanges | -600.00K | |||
| NetPPEPurchaseAndSale | 0.00 | -14.30K | -14.07K | -130.41K |
| SaleOfPPE | 0.00 | 2.27K | 0.00 | |
| PurchaseOfPPE | 0.00 | -14.30K | -16.34K | -130.41K |
| OperatingCashFlow | -18.22M | -40.89M | -34.96M | -31.22M |
| CashFlowFromContinuingOperatingActivities | -18.22M | -40.89M | -34.96M | -31.22M |
| ChangeInWorkingCapital | -2.68M | 2.97M | 3.15M | -5.57M |
| ChangeInOtherWorkingCapital | 252.80K | |||
| ChangeInOtherCurrentLiabilities | -209.02K | -96.71K | -263.38K | -258.59K |
| ChangeInOtherCurrentAssets | 212.88K | 89.83K | 253.10K | 252.80K |
| ChangeInPayablesAndAccruedExpense | -4.55M | 302.92K | 2.25M | -1.07M |
| ChangeInPrepaidAssets | 1.86M | 2.68M | 917.31K | -4.49M |
| OtherNonCashItems | 1.82M | -440.00K | -414.99K | 2.31M |
| StockBasedCompensation | 791.64K | 1.34M | 2.55M | 4.67M |
| AssetImpairmentCharge | 600.00K | 3.19M | 1.87M | 0.00 |
| DeferredTax | 0.00 | -409.02K | 0.00 | |
| DeferredIncomeTax | 0.00 | -409.02K | 0.00 | |
| DepreciationAmortizationDepletion | 30.76K | 67.13K | 77.46K | 86.07K |
| DepreciationAndAmortization | 30.76K | 67.13K | 77.46K | 86.07K |
| Depreciation | 30.76K | 67.13K | ||
| OperatingGainsLosses | -5.58M | 1.32M | ||
| GainLossOnInvestmentSecurities | -5.58M | 1.32M | ||
| NetIncomeFromContinuingOperations | -13.19M | -48.93M | -42.20M | -32.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HEPA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|